Part D Preserves Access to Medicines for Beneficiaries with Diabetes

06.12.13 | By

The Annals of Internal Medicine recently published a study that compared prescription diabetes medicine use between Medicare Part D and the Veterans Affairs (VA) program, specifically focusing on generic drug use. The study and subsequent media coverage overlook some important facts about prescription drug coverage in these two programs.

Adhering to Heart Health

06.12.13 | By

Every 39 seconds an American dies from cardiovascular disease, and more than 83 million Americans have at least one type of the disease, the American Heart Association (AHA) reports. But today, America’s biopharmaceutical research companies are developing 215 medicines for two of the leading causes of death of Americans – heart disease and stroke. 

More Than 200 Innovative Medicines in Development For Heart Disease and Stroke

WASHINGTON, D.C. (June 12, 2013) – America’s biopharmaceutical research companies are developing 215 medicines for two of the leading causes of death of Americans – heart disease and stroke, according to a new report and overview released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).

Week in Review: Innovation Provides Value for Patients…And Everyone Else, Too

06.07.13 | By

Medical innovation does an enormous amount of good for patients, but there is also a broader societal impact: innovative research positively impacts the economy, as well.

U.S. Policymakers Can’t Ignore Storm Clouds from India

06.07.13 | By

This week, the Commerce Department released the latest data on America’s trade balance, and the news was not good. While exports of U.S. goods and services rose in April, our trade deficit grew to $40.3 billion, up more than 8 percent in a single month.

PhRMA Statement on Sequestration of PDUFA User Fees

WASHINGTON, D.C. (June 7, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) Vice President of Scientific and Regulatory Affairs Sascha Haverfield, Ph.D., issued the following statement today:

“PhRMA remains deeply concerned about the impact of sequestration on the Food and Drug Administration’s (FDA) ability to fulfill its critical public health mission by fostering timely patient access to safe and effective new medicines. 

Standardized CoI Policies Can Help Foster Collaboration and Innovation

06.07.13 | By

Earlier this week, PhRMA’s Gabriela Lavezzari, Assistant Vice President, Scientific Affairs, participated in an Institute of Medicine (IoM) workshop, titled “Conflict of Interest in Medical Innovation: Assuring Integrity while Facilitating Innovation in Medical Research.” Gabriela presented on the impact of conflict of interest (CoI) policies on medical i

Governor Pence Calls for Life Sciences Expansion in Indiana

06.04.13 | By

At the latest Research in Your Backyard event in Indiana today, Indiana Governor Mike Pence acknowledged the many positive impacts of the clinical research conducted by biopharmaceutical companies in the Hoosier State and said he’d like to expand the partnership. 

Cooperation For Patient Health

06.04.13 | By

At the American Society of Clinical Oncology (ASCO) meeting, U.S. Food and Drug Administration (FDA) Commissioner Dr.

New Report Shows Over 3,200 Clinical Trials of Medicines Conducted by Indiana Research Institutions Since 1999

WASHINGTON, D.C. (June 4, 2013) –  Working in collaboration with Indiana clinicians and research institutions, America’s biopharmaceutical research companies have conducted 3,266 clinical trials of new medicines in Indiana over the last 13 years, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).


Subscribe to RSS - Opinion